CONMED Corp — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED Corp (CNMD)
CIK: 0000816956
Period of Report: 2023-03-13

Reporting Person: Garner Todd W (Executive Vice President & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-13	Common Stock	M	30000	$50.61	Acquired	31115	Direct
2023-03-13	Common Stock	S	1300	$88.7819	Disposed	29815	Direct
2023-03-13	Common Stock	S	6849	$90.3044	Disposed	22966	Direct
2023-03-13	Common Stock	S	17926	$91.1009	Disposed	5040	Direct
2023-03-13	Common Stock	S	3825	$91.9452	Disposed	1215	Direct
2023-03-13	Common Stock	S	100	$92.63	Disposed	1115	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-13	Options To Purchase Common Stock	$50.61	M	30000	Disposed	2028-01-02	Common Stock (30000)	Direct

Footnotes

F1: These trades were made pursuant to a plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.15 to $88.99. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.61 to $90.595. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.615 to $91.61. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.625 to $92.45. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F6: Each Stock Option represents a contingent right to receive one share of common stock, par value $0.001, per share of Conmed Corporation (the "Company") and was granted outside of the Company's existing equity plan as "employment inducement grants" under NASDAQ Listing Rule 5635(c)(4) and vest in equal amounts (20%) over a five year period on the January 2 anniversary date of the award, as further described in the Current Report filed with the SEC by the Company on January 2, 2018.